We investigated peripheral blood progenitor cell (PBPC) mobilization by disease-specific chemotherapy in patients with metastatic soft tissue sarcoma (STS). Nine patients, five females and four males, aged 12-51 years, pretreated by one to nine courses of cytotoxic chemotherapy, underwent STS-specific mobilization followed by G-CSF at 5 g/kg/day. ؉ cells/kg, exhibited delayed ANC recovery on day ؉37 and failed to recover platelets until hospital discharge on day +55. We conclude that in patients with metastatic STS, who are pretreated by standard chemotherapy, PBPC can be mobilized by a further course of STS-specific chemotherapy plus G-CSF. One to four conventional-volume aphereses result in PBPC autografts that can serve as hematopoietic rescue for patients scheduled for HDCT.
disease. 1 In this situation the use of cytotoxic drugs has been extensively investigated, but only doxorubicin and ifosfamide have consistently shown response rates of 20-30%. 2, 3 Combination of doxorubicin and ifosfamide results in slightly better remission rates ranging from 30 to 40%. 4, 5 Treatment of patients who do not respond to these drugs is very difficult because only few salvage regimens exist. 6, 7 There is strong evidence for a dose-response relationship for doxorubicin and ifosfamide. 8, 9 For optimal response rates it seems essential to achieve a dose intensity of greater than 65 mg/m 2 for doxorubicin and greater than 5 g/m 2 for ifosfamide. 10, 11 In the last decade, hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have entered clinical trials in an attempt to administer escalated-dose chemotherapy regimens without inducing fatal neutropenia. 12, 13 More recently, the use of hematopoietic stem/progenitor cells has circumvented myelotoxicity as the dose-limiting toxicity in clinical trials. 14, 15 The aim of this study was to demonstrate peripheral blood progenitor cell (PBPC) mobilization by diseasespecific chemotherapy in pretreated patients with metastatic STS scheduled for high-dose chemotherapy (HDCT).
Patients and methods

Patients
Nine patients, five females and four males, at a median age of 34 years (range 12-51) were suffering from STS. Patients were referred for PBPC mobilization and collection with a median of two courses (range 1-9) of previous cytotoxic chemotherapy based on epidoxorubicin/ adriamycin (EDR/ADM) and ifosfamide (IFO).
PBPC mobilization
PBPC were mobilized by ADM 60 mg/m 2 on day 1 or EDR 50 mg/m 2 days 1-2 and IFO 1600 mg/m 2 days 1-5 (n = 6), cisplatinum (CIP) 100 mg/m 2 day 1 and dacarbazine (DTIC) 250 mg/m 2 days 1-5 (n = 1), carboplatinum (CAP) 300 mg/m 2 day 1, etoposide (VP-16) 140 mg/m 2 days 1-3 and IFO 1200 mg/m 2 days 1-3 (n = 1) or dactinomycin (DACT) 0.5 mg/m 2 days 1-3, VP-16 200 mg/m 2 days 1-3 and IFO 2400 mg/m 2 days 1-3 (n = 1). Subcutaneous G-CSF was started 24 h after the end of chemotherapy at 5 g/kg/day and continued until completion of PBPC harvest.
PBPC collection
Leukaphereses were performed on 1-4 consecutive days with COBE Spectra (COBE BCT, Martinsried, Germany) and/or Fresenius AS104 (Fresenius AG, Bad Homburg, Germany). A total blood volume of 8-12 l per apheresis was processed through double-lumen apheresis catheters or by venous punctures for 2-4 h at flow rates of 40-70 ml/min. Aphereses were started when numbers of circulating PBPC, identified as CD34-positive (CD34 + ) cells, exceeded 10/l of peripheral blood (PB).
Laboratory analysis
Prior to leukaphereses patients were monitored by serial PB samples for blood cell counts (NE-7000, TOA Sysmex, Kobe, Japan) and circulating CD34
+ cells (FACScan, Becton Dickinson, San Jose, CA, USA), as recently described. 16 Samples were taken from leukapheresis products to determine the number of MNC and CD34
+ cells collected. Yields of cumulative harvests were calculated per kg body weight in individual patients. PBPC concentrates were cryopreserved with a final dimethyl sulfoxide (DMSO, Laboratoires Bruneau, Boulogne-Billancourt, France) concentration of 10%. Suspensions were frozen in cryopreservation bags (Gambro, Hechingen, Germany) to Ϫ100°C in a controlled-rate freezer (Kryo 10 Series, Planar Products, Sunbury-on-Thames, UK). Frozen concentrates were stored at Ϫ196°C in liquid nitrogen. Granulocytemacrophage colony-forming units (CFU-GM) were assessed from frozen/thawed samples of single apheresis products using a semisolid clonogenic culture technique. 17 
HDCT regimens
Five patients received cyclophosphamide (CTX) 60 mg/kg days 1-2, VP-16 600 mg/m 2 days 1-4 and mitoxantrone (MOX) 15 mg/m 2 days 1-4. CAP 500 mg/m 2 days 1-3, VP-16 600 mg/m 2 days 1-4 and IFO 2500 mg/m 2 days 1-4 were administered to three patients.
PBPC reinfusion
The day of PBPC reinfusion was designated as day 0. The frozen concentrates were thawed at 37°C in a water bath and reinjected immediately into the recipients via a central venous catheter. No attempt was made to eliminate DMSO from thawed PBPC products.
Definition of hematopoietic engraftment
Time to reconstitution of hematologic function was defined as the number of days from PBPC reinfusion (day 0) when the absolute neutrophil count (ANC) and platelets exceeded 0.5 ϫ 10 3 /l and 20 ϫ 10 3 /l, respectively, remaining above these levels during the post-transplantation course.
Supportive care
All patients were cared for in single rooms under reverse isolation procedures. Prophylactic medication included suspension and aerosol of amphotericin B and ciprofloxazine. Antibiotic combination therapy was administered for fever greater than 38°C. For documented fungal infection or persistent fever intravenous (i.v.) amphotericin B was added. Antibiotics and antifungal treatment were stopped after hematologic recovery and absence of infection. Red blood cell (RBC) concentrates were transfused to maintain the hemoglobin level between 8 and 10 g/dl and single-donor platelet concentrates were given to keep platelet counts above 10 ϫ 10 3 /l. Blood products were depleted from WBC by bedside filtration and irradiated with 25 Gy. To accelerate hematopoietic recovery, patients received G-CSF (5 g/kg/day) as continuous infusion from day +1 until WBC counts exceeded 5.0 ϫ 10 3 /l.
Results
Patient characteristics
At diagnosis four patients were suffering from local STS and five patients had metastatic disease. Patients with local STS relapsed following surgery/radiotherapy with metastases 8-30 months after diagnosis. Thus all patients had metastatic disease prior to PBPC mobilization. Premobilization cytotoxic chemotherapy based on EDR or ADM plus IFO resulted in four partial remissions (PR) and three stable diseases (SD). Two cases were too early for response evaluation at the time of mobilization (Table 1) .
PBPC mobilization
PBPC mobilization was initiated a median of 8 months (range 1-44) following diagnosis (Table 1) . Mobilization regimens were determined by disease response to premobilization chemotherapy, the drugs administered during previous courses and/or cumulative doses of ADM. Four patients HA, WK, EI and SB with only one to two courses of EDR/IFO-pretreatment continued with the same chemotherapy, whereas patient RW with four courses of EDR/IFO changed to ADM/IFO. Patient SK with two cycles of ADM/IFO received a further course of ADM/IFO. Patient HC changed from ADM/IFO to CIP/DTIC because of extensive ADM-pretreatment (nine courses). Patient KM with lung metastases and poor response after two courses of ADM/IFO changed to CAP/VP-16/IFO. Patient EC was treated according to a pediatric protocol and aphereses were performed after DACT/VP-16/IFO (Tables 1 and 2 ). Eight to 11 days from beginning mobilization chemotherapy five patients developed cytopenia with WBC counts 0.2-0.9 ϫ 10 3 /l (Table 2 ). Patient EI with 0.2 ϫ 10 3 WBC/l after EDR/IFO experienced fever of unknown origin (FUO), which resolved after 4 days of i.v. antibiotic treatment. Another episode of FUO occurred in patient EC with 0.3 ϫ 10 3 WBC/l, who was mobilized by DACT/VP-16/IFO. She needed 2 RBC units and 2 single-donor platelet concentrates and recovered after 7 days of i.v. antibiotic treatment. In the other patients no infectious or bleeding episodes were noted and no RBC/PLT units were transfused in the recovery phase of mobilization chemotherapy. c Response evaluation too early after one course of chemotherapy. F = female; M = male; EDR = epidoxorubicin; ADM = adriamycin; IFO = ifosfamide; VCR = vincristine; DACT = dactinomycin; DTIC = dacarbazine. + cells/kg collected by cumulative aphereses. NA = not available; EDR = epidoxorubicin; ADM = adriamycin; IFO = ifosfamide; CIP = cisplatinum; DTIC = dacarbazine; CAP = carboplatinum; VP-16 = etoposide; DACT = dactinomycin; PBPC = peripheral blood progenitor cells; WBC = white blood cells; PLT = platelets.
PBPC collection
Conventional-volume aphereses (8-12 l) started on median day 15 (range 13-18) from the first day of mobilization chemotherapy at CD34 + cells Ͼ10/l. At the start of aphereses seven patients had circulating CD34 + cells Ͼ10/l (range 13.3-207.8) and needed one to two procedures for PBPC harvest. Patients RW and HC with four and nine cycles of premobilization chemotherapy failed to achieve this threshold following mobilization. They underwent three and four aphereses, respectively, resulting in 1.1 ϫ 10 6 and 2.0 ϫ 10 6 CD34 + cells/kg (Table 2) . On the first day of leukaphereses patients had the following median PB counts: 25.8 ϫ 10 All patients showed a decrease of platelet counts following aphereses, but no bleeding occurred.
Hematopoietic engraftment following HDCT
One to 6 months after PBPC collection, eight patients underwent HDCT and PBPC reinfusion. + cells/kg exhibited delayed ANC recovery (day +37) and failed to achieve platelets Ͼ20 ϫ 10 3 /l by hospital discharge (day +55) ( Table 3 ). Not reached until hospital release on day +55. NA = not available; ANC = absolute neutrophil count; PLT = platelets.
866
Discussion
HDCT regimens followed by hematopoietic support with autologous bone marrow and/or peripheral blood are increasingly used for the treatment of various solid tumors. 18, 19 However, HDCT is an investigational treatment modality for metastatic STS and available data are scanty. 20 There are only few phase II trials dealing with HDCT and autologous hematopoietic rescue in patients suffering from STS. [21] [22] [23] [24] [25] In most studies patients received bone marrow support for hematopoietic reconstitution following HDCT. [21] [22] [23] [24] It is well-known, however, that recovery of hematopoiesis occurs significantly faster after PBPC than following bone marrow rescue. In a randomized study it has been shown that patients with germ cell cancer, who underwent HDCT with subsequent PBPC reinfusion, recovered hematopoiesis significantly faster than patients rescued by bone marrow. 15 Therefore, the present study focused on the feasibility of mobilization and collection of PBPC in pretreated patients with metastatic STS. Mobilization of PBPC is usually performed by cyclophosphamide and/or growth factor in various malignant diseases. [26] [27] [28] We and others, however, have shown that disease-specific cytotoxic chemotherapy plus growth factor efficiently mobilized PBPC from bone marrow into PB in patients with solid tumors and hematologic malignancies. and were approximately 42-fold higher than the baseline values. Unfortunately, in that study no data on circulating CD34
+ cells were reported. In the present study, STS patients exhibited preapheresis
CD34
+ cell counts following disease-specific chemotherapy plus G-CSF which were comparable to CD34 + cell numbers demonstrated in patients with lymphoma/myeloma and germ cell cancer after disease-oriented chemotherapy. 16 Again, collected MNC, CD34
+ cells and CFU-GM were comparable to apheresis collections of patients suffering from hematologic and non-hematologic malignancies. 16 However, two patients with four and nine courses of cytotoxic pretreatment failed to reach CD34 + cells Ͼ10/l, a threshold value that should be exceeded at the start of leukapheresis. They underwent three and four aphereses, respectively, whereas the other seven patients with a median of two courses (1-3) of pretreatment needed one to two procedures for PBPC collection. STS-specific chemotherapy led, despite G-CSF administration, in five of nine patients to pronounced myelosuppression with WBC counts 0.2-0.9 ϫ 10 3 /l. Two patients required i.v. antibiotics because of FUO and recovered after 4-7 days of treatment. No other life-threatening complications were seen during recovery from mobilization chemotherapy. Eight patients underwent HDCT and PBPC reinfusion. Seven patients recovered hematopoiesis timely in a median of 12 days for ANC Ͼ0.5 ϫ 10 3 /l and 14 days for platelets Ͼ20 ϫ 10 3 /l, time-periods which have been reported in patients with solid tumors and hematologic diseases following HDCT and PBPC rescue. 15, 16 One patient, however, exhibited delayed ANC recovery on day +37 and failed to recover platelets until hospital discharge on day +55. The day of platelet recovery could not be determined exactly, because the patient reached platelet numbers Ͼ20 ϫ 10 3 /l after hospital release. The patient received a cell dose of 1.6 ϫ 10 6 CD34 + cells/kg for hematopoietic rescue, which was below the threshold considered to be sufficient for rapid and safe hematopoietic recovery. 29, 33 Unfortunately, in this patient no CFU-GM assays were available from frozen/thawed PBPC samples, which could have contributed to more information on the quality of the autograft.
In conclusion, in STS patients with cytotoxic pretreatment PBPC mobilization is feasible by a further course of disease-specific chemotherapy plus G-CSF. One to four conventional-volume leukaphereses result in PBPC autografts that can serve as hematopoietic rescue for appropriate patients scheduled for HDCT. Nevertheless, because the role of HDCT in the management of metastatic STS remains to be evaluated in controlled trials, careful clinical management is required to minimize treatment-related risks in these patients. Therefore, the content of collected/ reinfused PBPC autografts should exceed 2.5 ϫ 10 6 CD34
+ cells/kg, as suggested for rapid and safe recovery of hematopoiesis following HDCT in patients with solid tumors and hematologic diseases. 29, 33 
